One of the difficulties faced by those trying to unlock the value in data collected by systems from individuals is that even when the data can be made anonymous, the owners of the data are reluctant to share it with third parties. But in clinical trials, and in other medical research projects, data is routinely collected, shared and analysed. What does this tell us about the frameworks for trust that are needed to make the most of “big data”?
What were the most significant things to come out of the global analyst summit hosted in April by Huawei – one of the biggest telecoms equipment vendors? I’ve had a few days to reflect, and these are my conclusions.
Submitted by Danny Dicks on 22 April 2015 - 11:27pm
To paraphrase Thomas Edison, “innovation is 1% inspiration, 79% perspiration, and 20% organisation”. In a wide-ranging presentation at the Huawei Global Analyst Summit in Shenzhen this April, Ryan Ding, the company’s president of products and solutions, explained how the ICT vendor had structured innovation into three layers – recognising that no company, not even one as big as Huawei, has a monopoly of new ideas in all the areas in which its products and services are used.